306 related articles for article (PubMed ID: 17339109)
1. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Workman P; Waterfield MD; Parker P
Bioorg Med Chem Lett; 2007 May; 17(9):2438-42. PubMed ID: 17339109
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kaizawa H; Kawaguchi K; Ishikawa N; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Waterfield MD; Parker P; Workman P
Bioorg Med Chem; 2007 Jan; 15(1):403-12. PubMed ID: 17049248
[TBL] [Abstract][Full Text] [Related]
3. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
5. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
[TBL] [Abstract][Full Text] [Related]
7. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
[TBL] [Abstract][Full Text] [Related]
8. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
Gazivoda T; Sokcević M; Kralj M; Suman L; Pavelić K; De Clercq E; Andrei G; Snoeck R; Balzarini J; Mintas M; Raić-Malić S
J Med Chem; 2007 Aug; 50(17):4105-12. PubMed ID: 17672445
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 2,4,6-functionalized derivatives of pyrido[2,3-d]pyrimidines as cytotoxic agents and apoptosis inducers.
Sanmartín C; Domínguez MV; Cordeu L; Cubedo E; García-Foncillas J; Font M; Palop JA
Arch Pharm (Weinheim); 2008 Jan; 341(1):28-41. PubMed ID: 18161903
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity.
Xie F; Zhao H; Zhao L; Lou L; Hu Y
Bioorg Med Chem Lett; 2009 Jan; 19(1):275-8. PubMed ID: 19028425
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1.
Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Sim T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Ohmori O; Caldwell J; Gray N; He Y
Bioorg Med Chem Lett; 2006 Apr; 16(8):2173-6. PubMed ID: 16458503
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agents 6. Synthesis, structure-activity relationships, and biological evaluation of spiro[imidazolidine-4,3'-thieno[2,3-g]quinoline]-tetraones and spiro[thieno[2,3-g]quinoline-3,5'-[1,2,4]triazinane]-tetraones with potent antiproliferative activity.
Bolognese A; Correale G; Manfra M; Esposito A; Novellino E; Lavecchia A
J Med Chem; 2008 Dec; 51(24):8148-57. PubMed ID: 19053767
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992
[TBL] [Abstract][Full Text] [Related]
16. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
17. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
VanderWel SN; Harvey PJ; McNamara DJ; Repine JT; Keller PR; Quin J; Booth RJ; Elliott WL; Dobrusin EM; Fry DW; Toogood PL
J Med Chem; 2005 Apr; 48(7):2371-87. PubMed ID: 15801830
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of analogues of the anti-tumor alkaloid naamidine A.
Aberle N; Catimel J; Nice EC; Watson KG
Bioorg Med Chem Lett; 2007 Jul; 17(13):3741-4. PubMed ID: 17462892
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
